IMC Chicago’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.18B | Buy |
1,287,800
+53,900
| +4% | +$54.6M | 0.43% | 41 |
|
|
2025
Q4 | $1.33B | Buy |
1,233,900
+199,600
| +19% | +$191M | 0.48% | 37 |
|
|
2025
Q3 | $789M | Buy |
1,034,300
+336,000
| +48% | +$250M | 0.29% | 56 |
|
|
2025
Q2 | $544M | Buy |
698,300
+110,700
| +19% | +$86M | 0.24% | 55 |
|
|
2025
Q1 | $485M | Sell |
587,600
-229,000
| -28% | -$191M | 0.27% | 45 |
|
|
2024
Q4 | $630M | Buy |
816,600
+89,200
| +12% | +$73.9M | 0.29% | 41 |
|
|
2024
Q3 | $644M | Sell |
727,400
-125,700
| -15% | -$113M | 0.35% | 36 |
|
|
2024
Q2 | $772M | Buy |
853,100
+145,800
| +21% | +$117M | 0.47% | 30 |
|
|
2024
Q1 | $550M | Buy |
707,300
+139,300
| +25% | +$99.1M | 0.34% | 36 |
|
|
2023
Q4 | $331M | Buy |
568,000
+125,400
| +28% | +$73.2M | 0.22% | 48 |
|
|
2023
Q3 | $238M | Buy |
442,600
+179,200
| +68% | +$92.3M | 0.21% | 43 |
|
|
2023
Q2 | $124M | Buy |
263,400
+120,100
| +84% | +$50.4M | 0.11% | 80 |
|
|
2023
Q1 | $49.2M | Sell |
143,300
-53,000
| -27% | -$17.9M | 0.06% | 173 |
|
|
2022
Q4 | $71.8M | Buy |
196,300
+57,600
| +42% | +$20.4M | 0.11% | 102 |
|
|
2022
Q3 | $44.8M | Buy |
138,700
+72,800
| +110% | +$23.1M | 0.06% | 152 |
|
|
2022
Q2 | $21.4M | Buy |
65,900
+20,600
| +45% | +$6.18M | 0.03% | 285 |
|
|
2022
Q1 | $13M | Buy |
45,300
+600
| +1% | +$154K | 0.01% | 416 |
|
|
2021
Q4 | $12.3M | Sell |
44,700
-23,500
| -34% | -$5.96M | 0.01% | 454 |
|
|
2021
Q3 | $15.8M | Sell |
68,200
-32,400
| -32% | -$8M | 0.02% | 404 |
|
|
2021
Q2 | $23.1M | Sell |
100,600
-2,700
| -3% | -$542K | 0.03% | 302 |
|
|
2021
Q1 | $19.3M | Buy |
103,300
+50,800
| +97% | +$9.94M | 0.03% | 302 |
|
|
2020
Q4 | $8.86M | Buy |
52,500
+32,300
| +160% | +$4.82M | 0.01% | 425 |
|
|
2020
Q3 | $2.99M | Sell |
20,200
-22,700
| -53% | -$3.51M | ﹤0.01% | 511 |
|
|
2020
Q2 | $7.04M | Sell |
42,900
-16,000
| -27% | -$2.46M | 0.01% | 319 |
|
|
2020
Q1 | $8.17M | Buy |
58,900
+2,300
| +4% | +$316K | 0.02% | 237 |
|
|
2019
Q4 | $7.44M | Buy |
56,600
+37,700
| +199% | +$4.37M | 0.02% | 276 |
|
|
2019
Q3 | $2.11M | Sell |
18,900
-2,600
| -12% | -$289K | 0.01% | 450 |
|
|
2019
Q2 | $2.38M | Sell |
21,500
-26,700
| -55% | -$3.14M | 0.01% | 387 |
|
|
2019
Q1 | $6.25M | Buy |
48,200
+29,700
| +161% | +$3.61M | 0.02% | 209 |
|
|
2018
Q4 | $2.14M | Buy |
+18,500
| New | +$2.07M | 0.01% | 333 |
|
Other funds holding LLY
VCM
VPM
IMC Chicago's LLY Position: Q3 2025 in Review
IMC Chicago sold out of Eli Lilly (LLY) in Q3 2025, closing a stake of 17,293 shares — an estimated $12.9M sold.
IMC Chicago first reported a position in LLY in Q4 2018 and held it in 4 quarters. The position peaked at $37.6M in Q4 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- IMC Chicago reported no remaining Eli Lilly position as of Q3 2025 after selling out during the quarter.
- IMC Chicago sold 17,293 Eli Lilly shares in Q3 2025, an estimated $12.9M.
- IMC Chicago first reported a position in Eli Lilly in Q4 2018 and held it in 4 quarters.
- IMC Chicago's Eli Lilly position peaked at $37.6M in Q4 2024.
- 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.